Form 4: Merck Completes Cidara Therapeutics Acquisition

Cidara Therapeutics, Inc. has been acquired by Merck Sharp & Dohme LLC, with common shares tendered at $221.50 each.

Summary

• Cidara Therapeutics, Inc. (CDTX) has been acquired by Merck Sharp & Dohme LLC (Merck) through its wholly-owned subsidiary, Caymus Purchaser, Inc.
• The acquisition was completed on January 7, 2026, following a tender offer.
• Common Shares were acquired for $221.50 per share in cash.
• Series A Convertible Voting Preferred Stock was acquired for $15,505.00 per share in cash.
• All outstanding employee stock options became fully vested and exercisable immediately prior to the merger's effective time.
• Unexercised options were cancelled at the effective time and converted into a cash payment equal to the product of the number of shares subject to the option multiplied by the difference between the $221.50 merger consideration and the option's exercise price.
• Shane Ward, COO & CLO, disposed of 25,083 Common Stock shares at $221.50 per share as part of the merger.
• Ward also disposed of various employee stock options, which were cashed out based on the merger terms, including options with exercise prices ranging from $10.75 to $43.2.
• The exercise prices and number of securities for options were adjusted to reflect a 1-for-20 reverse stock split effected on April 24, 2024.
• 50 shares were acquired by Shane Ward through the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025, prior to the merger.

Sentiment

Score: 8

Explanation: The completion of the merger at a significant cash consideration per share is a positive outcome for Cidara Therapeutics shareholders, providing liquidity and a defined return. The cashing out of employee stock options also represents a positive financial event for employees like the reporting person.

Positives

• Shareholders received a definitive cash consideration for their shares, providing liquidity and a clear return.
• Employee stock options became fully vested and were cashed out, providing a financial benefit to option holders like Shane Ward.
• The acquisition by a major pharmaceutical company like Merck provides a strategic exit for Cidara Therapeutics and its investors.

Negatives

• Cidara Therapeutics, Inc. ceases to be an independent publicly traded company, eliminating future independent growth potential for public shareholders.
• Public shareholders no longer participate in any potential future upside of Cidara's pipeline or operations beyond the merger consideration.

Risks

• NA

Future Outlook

Cidara Therapeutics, Inc. is now a wholly-owned subsidiary of Merck Sharp & Dohme LLC, and as such, its independent future outlook as a publicly traded company has ceased. The filing does not provide a future outlook for the combined entity or Cidara's operations under Merck.

Industry Context

This acquisition reflects a common trend in the biopharmaceutical industry where larger pharmaceutical companies acquire smaller biotech firms to expand their pipelines, gain access to innovative technologies, or eliminate competition. Merck's acquisition of Cidara Therapeutics aligns with strategies to bolster therapeutic portfolios.

Comparison to Industry Standards

• The filing details the completion of an acquisition and the cash consideration paid per share. It does not provide sufficient information to compare the acquisition terms (e.g., valuation multiples, premium paid) to specific global benchmarks or comparable company transactions within the biopharmaceutical industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash consideration for their shares, providing a definitive return on investment.
• Employees (including option holders): Employee stock options were fully vested and cashed out, providing a financial benefit.
• Company (Cidara Therapeutics): Now operates as a private entity under Merck, potentially benefiting from Merck's resources and scale.

Next Steps

• Cidara Therapeutics, Inc. will continue operations as a wholly-owned subsidiary of Merck Sharp & Dohme LLC.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Merck, Merck Sharp & Dohme, Acquisition, Merger, Tender Offer, Form 4, Beneficial Ownership, Stock Options, Biotechnology, Pharmaceuticals